Literature DB >> 16949643

A novel tumor marker, Niban, is expressed in subsets of thyroid tumors and Hashimoto's thyroiditis.

Fumihiko Matsumoto1, Hiroaki Fujii, Masaaki Abe, Kazunori Kajino, Toshiyuki Kobayashi, Toshiharu Matsumoto, Katsuhisa Ikeda, Okio Hino.   

Abstract

Niban is a recently identified molecular marker of renal carcinogenesis in the Tsc2 gene-mutant Eker rat. Niban expression is most dramatically increased in the early stage of renal carcinogenesis and might decline during malignant progression. Niban is also expressed in various histologic types of human renal cell carcinoma. Therefore, Niban might be a good marker for renal carcinogenesis in both animal models and humans. In the present study, we examined Niban expression in various thyroid lesions by immunohistochemical staining using polyclonal rabbit antihuman Niban antibody. Normal thyroid tissue never stained for Niban. Niban was most frequently expressed in tumors with oxyphilic cytoplasm, including oxyphilic variants of papillary carcinoma (4/4 = 100%), oxyphilic variants of follicular adenoma (7/7 = 100%), and oxyphilic variants of follicular carcinoma (5/5 = 100%). Eighty-one percent (44/54) of papillary carcinoma cases, including microcarcinomas, and follicular variants were also positively stained for Niban at variable intensities. Follicular carcinomas were less frequently and less intensely stained. In nonneoplastic lesions, cells were rarely positively stained. In Hashimoto's thyroiditis, scattered cells with oxyphilic cell metaplasia were weakly Niban-positive. Reverse transcriptase-polymerase chain reaction and Western blot analysis of frozen tissue confirmed Niban expression at the molecular level in 4 cases of papillary carcinoma. Taken together, Niban expression is up-regulated in various types of thyroid tumors. We postulate that Niban expression may play an important role in the tumorigenic process of the thyroid in several scenarios. (1) Niban expression may be closely related to the carcinogenic process, especially from the early stage of papillary thyroid carcinoma. (2) Niban may be closely associated with altered mitochondrial functions in preneoplastic and neoplastic processes of the thyroid. (3) Niban may be a molecular marker of the oxyphilic phenotype under various conditions. Further functional studies of Niban will clarify the role of Niban in various thyroid lesions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16949643     DOI: 10.1016/j.humpath.2006.06.022

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  17 in total

1.  PVALB, a new Hürthle adenoma diagnostic marker identified through gene expression.

Authors:  Janete M Cerutti; Gisele Oler; Rosana Delcelo; Rene Gerardt; Pedro Michaluart; Sandro J de Souza; Pedro A F Galante; Peng Huang; Gregory J Riggins
Journal:  J Clin Endocrinol Metab       Date:  2010-10-06       Impact factor: 5.958

2.  AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis.

Authors:  Haitao Ji; Zhiyong Ding; David Hawke; Dongming Xing; Bing-Hua Jiang; Gordon B Mills; Zhimin Lu
Journal:  EMBO Rep       Date:  2012-06-01       Impact factor: 8.807

3.  miR-135a deficiency inhibits the AR42J cells damage in cerulein-induced acute pancreatitis through targeting FAM129A.

Authors:  Kai-Kai Zhang; Shan-Shan Yu; Gui-Yun Li; Lian He; Xian-Quan Liang
Journal:  Pflugers Arch       Date:  2019-11-15       Impact factor: 3.657

4.  Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.

Authors:  Sophia Doll; Anatoly Urisman; Juan A Oses-Prieto; David Arnott; Alma L Burlingame
Journal:  Mol Cell Proteomics       Date:  2016-11-10       Impact factor: 5.911

5.  FAM129B/MINERVA, a novel adherens junction-associated protein, suppresses apoptosis in HeLa cells.

Authors:  Song Chen; Hedeel Guy Evans; David R Evans
Journal:  J Biol Chem       Date:  2010-12-09       Impact factor: 5.157

6.  P2X7R antagonism after subfailure overstretch injury of blood vessels reverses vasomotor dysfunction and prevents apoptosis.

Authors:  Weifeng Luo; Daniel Feldman; Reid McCallister; Colleen Brophy; Joyce Cheung-Flynn
Journal:  Purinergic Signal       Date:  2017-09-13       Impact factor: 3.765

7.  Systems biology and in vitro validation identifies family with sequence similarity 129 member A (FAM129A) as an asthma steroid response modulator.

Authors:  Michael J McGeachie; George L Clemmer; Boris Hayete; Heming Xing; Karl Runge; Ann Chen Wu; Xiaofeng Jiang; Quan Lu; Bruce Church; Iya Khalil; Kelan Tantisira; Scott Weiss
Journal:  J Allergy Clin Immunol       Date:  2018-03-02       Impact factor: 10.793

8.  Employing genetic markers to improve diagnosis of thyroid tumor fine needle biopsy.

Authors:  Janete M Cerutti
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

9.  The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors.

Authors:  Eva Sigstad; Elisabeth Paus; Trine Bjøro; Aasmund Berner; Krystyna Kotanska Grøholt; Lars H Jørgensen; Manuel Sobrinho-Simões; Ruth Holm; David J Warren
Journal:  Mod Pathol       Date:  2011-12-09       Impact factor: 7.842

10.  Endogenous avidin biotin activity (EABA) in thyroid pathology: immunohistochemical study.

Authors:  Barbara Nikiel; Mykola Chekan; Michal Jarząb; Dariusz Lange
Journal:  Thyroid Res       Date:  2009-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.